Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Are ambulatory.~* Diagnosis of radiographic axial spondyloarthritis (rad-xSpA) with sacroiliitis defined radiographically according to the modified New York criteria.~* Participants have a history of back pain ≥3 months with age at onset \<45 years.~* In the past had an inadequate response to at least 2 non-steroidal anti-inflammatory drugs (for duration 4 weeks) or cannot tolerate NSAIDS.~* If taking NSAIDS be on a stable dose for at least 2 weeks prior to randomization.~* Have a history of prior therapy for axSpa for at least 12 weeks prior to screening.~Exclusion Criteria:~* Have total ankylosis of the spine.~* Have received any prior, or are currently receiving, treatment with biologics, tumor necrosis factor inhibitors or other immunomodulatory agents.~* Have recently received a live vaccine within 12 weeks or have had a vaccination with Bacillus Calmette-Guerin (BCG) within the past year.~* Have an ongoing or serious infection within the last 12 weeks or evidence of active tuberculosis.~* Have a compromised immune system.~* Have any other serious and/or uncontrolled diseases.~* Have either a current diagnosis or a recent history of malignant disease.~* Have had major surgery within 8 weeks of baseline, or will require surgery during the study.~* Are pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Q2W Ixekizumab (Type: EXPERIMENTAL): Double Blind Period: Starting dose of 80 or 160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline followed by 80 mg ixekizumab given SC every two weeks (Q2W) to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q2W from week 16 to week 52.
- Q4W Ixekizumab (Type: EXPERIMENTAL): Double Blind Period: Starting dose of 80 or 160 mg ixekizumab given SC at baseline followed by 80 mg ixekizumab given SC every four weeks (Q4W) to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q4W from week 16 to week 52.
- Placebo (Type: PLACEBO_COMPARATOR): Double Blind Period: Placebo given SC Q2W to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q2W or Q4W from week 16 to week 52.
- Adalimumab (Type: ACTIVE_COMPARATOR): Double Blind Period: 40 mg Adalimumab given SC Q2W to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q2W or Q4W from week 20 to week 52.

Based on this trial design, predict the completion outcome and termination type (if applicable).